Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
JNJ Johnson & Johnson daily Stock Chart
Johnson & Johnson
IndexDJIA S&P500 P/E19.61 EPS (ttm)5.22 Insider Own0.02% Shs Outstand2.77B Perf Week0.62%
Market Cap283.25B Forward P/E15.94 EPS next Y6.42 Insider Trans-6.66% Shs Float2.77B Perf Month2.63%
Income14.72B PEG3.60 EPS next Q1.42 Inst Own67.50% Short Float0.92% Perf Quarter8.36%
Sales70.52B P/S4.02 EPS this Y18.50% Inst Trans0.21% Short Ratio2.98 Perf Half Y3.87%
Book/sh25.85 P/B3.96 EPS next Y3.90% ROA11.20% Target Price108.13 Perf Year-1.68%
Cash/sh13.48 P/C7.59 EPS next 5Y5.44% ROE21.00% 52W Range81.19 - 105.85 Perf YTD0.80%
Dividend3.00 P/FCF40.98 EPS past 5Y5.30% ROI18.40% 52W High-3.29% Beta0.63
Dividend %2.93% Quick Ratio2.20 Sales past 5Y3.70% Gross Margin69.20% 52W Low26.08% ATR1.09
Employees126500 Current Ratio2.50 Sales Q/Q-7.40% Oper. Margin25.70% RSI (14)64.42 Volatility0.70% 1.03%
OptionableYes Debt/Eq0.28 EPS Q/Q-27.70% Profit Margin20.90% Rel Volume0.28 Prev Close101.96
ShortableYes LT Debt/Eq0.20 EarningsOct 13 BMO Payout54.80% Avg Volume8.50M Price102.37
Recom2.40 SMA201.24% SMA505.19% SMA2004.97% Volume2,353,779 Change0.40%
Oct-05-15Resumed Piper Jaffray Neutral $105
May-21-15Reiterated Deutsche Bank Hold $106 → $110
Dec-08-14Reiterated RBC Capital Mkts Outperform $110 → $114
Jul-16-14Reiterated Deutsche Bank Hold $102 → $107
Apr-17-14Reiterated Argus Buy $104 → $116
Apr-16-14Reiterated RBC Capital Mkts Outperform $104 → $106
Jan-10-14Downgrade Barclays Overweight → Equal Weight $99
Jan-07-14Upgrade RBC Capital Mkts Sector Perform → Outperform $88 → $104
Dec-16-13Reiterated Deutsche Bank Hold $93 → $95
Jul-18-13Reiterated Argus Buy $96 → $104
Jul-17-13Reiterated Barclays Overweight $95 → $99
Jul-17-13Downgrade Deutsche Bank Buy → Hold $92 → $93
Apr-18-13Reiterated Argus Buy $80 → $96
Apr-15-13Reiterated Barclays Overweight $85 → $95
Apr-12-13Reiterated Deutsche Bank Buy $82 → $87
Mar-26-13Reiterated UBS Buy $81 → $87
Jan-11-13Reiterated UBS Buy $76 → $78
Jan-04-13Upgrade Deutsche Bank Hold → Buy $75 → $82
Nov-20-12Initiated Stifel Nicolaus Hold
Jul-18-12Reiterated RBC Capital Mkts Sector Perform $65 → $71
Nov-28-15 01:37PM  'Frozen,' 'Star Wars' fuel Band-Aid comeback for Johnson & Johnson at USA TODAY
Nov-27-15 08:39AM  1 Dividend Stock to Rule Them All at Motley Fool
Nov-26-15 12:04AM  Remicade: A Falling Drug in Mercks Immunology Franchise
Nov-25-15 05:57PM  Court revives Oregon suit over 'phantom recall' of Motrin
04:22PM  How Johnson & Johnson Spent $71 Billion in 12 Months at Motley Fool
09:04AM  Johnson & Johnson's Latest FDA Approval Could Spell Problems for Amgen at Motley Fool
Nov-24-15 08:44PM  Share A Photo, Give Back In A Snap PR Newswire
12:40PM  Gilead's (GILD) Cocktail HIV Drug Genvoya Approved in EU
07:41AM  This Metric Implies That It Might Be Time to Buy Big Pharma Stocks at Motley Fool
Nov-23-15 05:15PM  Takedas Ninlaro and Its Approval for Multiple Myeloma Treatment
03:52PM  3 Bear Market Stocks to Buy Now for Recession-Proof Dividends at Insider Monkey
10:12AM  Oxycontin Maker Says Chicago Trying To Usurp FDA's Authority at Forbes
08:46AM  3 Dividend Stocks You Don't Have to Babysit at Motley Fool
08:09AM  3 Health Care Stocks to Buy Now for Decades of Dividends at TheStreet
Nov-22-15 05:30PM  3 Bargain-Priced Dividend Stocks You Should Buy Now at TheStreet
03:26PM  Dow Back To Square One Year-To-Date With These Four Components Close To Break-Even at Forbes
02:54PM  5 Huge Stocks to Trade for Huge Gains at TheStreet
09:04AM  3 Top Stocks for Retirees to Buy at Motley Fool
07:00AM  3 Specialty-Drug Makers Trying to Spark Investor Interest -- Are They Buys? at Motley Fool
Nov-21-15 01:58PM  A Look At Investment Firms' Favorite Stocks In Q3
12:04PM  3 Healthcare Stocks You Don't Have to Babysit at Motley Fool
10:05AM  Darzalex: FDA Approved Human Anti-CD38 Monoclonal Antibody for MM
Nov-20-15 04:57PM  FDA approves Takeda drug for blood cancer multiple myeloma
04:35PM  Will Mallinckrodt (MNK) Surprise Earnings Again in Q4?
02:12PM  IBMs Watson Health Gets a Prestigious New Leader at Fortune
10:07AM  The Market Response to the FDAs Approval of Darzalex
08:34AM  Health care is the best pick for 2016, despite Thursday's drop: Strategist
Nov-19-15 02:07PM  Vertex Rises on Two EU Approvals for Drug, Leads XLVs Large-Caps
01:15PM  Clinical Trials Demonstrated Darzalexs Efficacy Profile
01:14PM  FDA Approval of Johnson & Johnsons Darzalex for Multiple Myeloma
10:23AM  Why Johnson & Johnson Stock Is a Better Buy Than Pfizer
10:22AM  Five Dividend-Payers That Could Turn $10,000 Into $5 Million In 65 Years at Forbes
10:10AM  Stock Market News for November 19, 2015
Nov-18-15 06:33PM  What's Ailing Small-Cap ETFs? A Look Inside A Leader at Investor's Business Daily
01:05PM  Global Drug Spending Will Reach $1.4 Trillion by 2020 at Fortune
08:11AM  These 5 Companies Own 491 Million Shares of Johnson & Johnson at Motley Fool
08:03AM  3 High-Dividend Stocks to Buy Before the Holiday Season at TheStreet
07:11AM  10 favorite stocks of value-fund managers at MarketWatch
06:35AM  Johnson & Johnson Pays a Healthy Dividend and Prescribes Strong Value at TheStreet
06:11AM  The PowerShares Dynamic Pharmaceuticals ETF: Holdings Breakdown
Nov-17-15 06:25PM  Lilly's Diabetes Drug Makes It a Turner Medical Fund Pick at TheStreet
04:30PM  Johnson & Johnson Announces $1.75 Million Donation to Save the Children to Support Syrian Humanitarian Refugee Crisis PR Newswire
04:27PM  Lies, Damned Lies, Corporate 'Earnings' and Up Markets
07:52AM  Early movers: HD, WMT, DKS, ANGI, GE, JNJ, PYPL & more at CNBC
07:39AM  Better Dividend Stock: Johnson & Johnson vs. Eli Lilly and Company at Motley Fool
Nov-16-15 05:52PM  Johnson & Johnson multiple myeloma drug wins accelerated OK
05:27PM  AbbVie Reports Encouraging Data on HCV Drug Viekira Pak
03:44PM  8 Value Stocks For Investors Worried About Risk
01:54PM  FDA approves J&J drug for advanced multiple myeloma Reuters
08:42AM  Best Dividend Stocks for 2016 at Motley Fool
Nov-15-15 03:18PM  Millennials Are Investing More in Stocks Than You May Think at Motley Fool
10:15AM  The Best Stocks in Conglomerates at Motley Fool
Nov-14-15 03:01AM  Very Little To Celebrate On World Diabetes Day at Forbes
Nov-13-15 03:38PM  5 Things Johnson & Johnson Wants You to Know at Motley Fool
01:17PM  Time To Buy Titans Like Apple, Berkshire And These Three Stocks at Forbes
11:06AM  Celgene Has a Strong Inflammation and Immunology Pipeline
04:06AM  Otezla Delivers Robust Revenue in 3Q15
Nov-12-15 12:46PM  6 'Defensive-Growth' Blue-Chip Stocks for the New Year at TheStreet
06:30AM  Lexington firms new sepsis test places it among life sciences giants at
Nov-11-15 05:51PM  Meet The Guy Who Says You're Not Rich Because You Don't Want To Be Rich at Forbes
10:45AM  Portola reversal agent for Xarelto succeeds in late stage trial
09:20AM  Lucas Capital Management Bets Big on Energy in Q4 at Insider Monkey
08:01AM  Should Healthcare Dividend Hunters Target AbbVie or Johnson & Johnson? at Motley Fool
Nov-10-15 07:01PM  Cramer Remix: It's the sexiest group out there at CNBC
07:00PM  Lightning Round: It's insane how much it went down at CNBC
03:01PM  Valeant may be haunted by same cost-cutting measures that befell J&J
12:42PM  How Johnson & Johnson Is Creeping Into Gileads Territory
10:45AM  Stocks to Eye with China's One-Child Policy Ended at Investopedia
07:45AM  Johnson & Johnson Inc. Named One of Canada's Top 100 Employers PR Newswire
Nov-09-15 10:08AM  What Do Analysts Recommend for Pfizer?
Nov-08-15 08:00AM  Activist stampede pushes board directors into shareholders' arms Reuters
Nov-07-15 12:03PM  Is Celgene's Otezla Coming of Age? at Motley Fool
09:03AM  Why Achillion Pharmaceuticals Shares Soared in October at Motley Fool
Nov-06-15 03:14PM  Why Achillion Pharmaceuticals Shares Are Roaring Higher Today at Motley Fool
01:10PM  Were finding out more and more about the risks of antibiotics, a medicine once considered a wonder drug
10:19AM  Better Dividend Stock: McDonald's vs. Johnson & Johnson at Motley Fool
09:59AM  Marijuana and Hepatitis C: What to Watch in 2016 at Motley Fool
09:44AM  Geron Beats on Q3 Earnings & Revenues, Imetelstat in Focus
07:40AM  A small biotech in a daunting field, Alzheon begins new Alzheimers study at
Nov-05-15 11:09PM  [$$] FDA Panel Seeks Tougher Antibiotic Labels at The Wall Street Journal
05:10PM  The US Economy Is Facing a Familiar Foe: The Strong Dollar
04:54PM  Gilead, AbbVie Asked by U.S. for Hepatitis C Pricing Options at Bloomberg
01:04PM  JOHNSON & JOHNSON Financials
Nov-04-15 01:52PM  Johnson & Johnson: A Dividend King at Investopedia
12:01PM  Johnson & Johnson Announces Agreement To Acquire Novira Therapeutics, Inc. PR Newswire
10:31AM  S&P 500 Index Futures Unchanged
Nov-03-15 04:37PM  Glaxo plans up to 20 new drug applications in near term
03:12PM  A revolutionary new way to treat HIV could be on its way
02:07PM  Eli Lillys Valuation Cheat Sheet 3Q15
01:29PM  J&J, ViiV: 2 injections every month or 2 could control HIV
01:00PM  Billionaire Ken Fishers Top Healthcare Stock Picks at Insider Monkey
10:20AM  Pharma ETFs to Buy on String of Q3 Earnings Beat
10:10AM  Enbrel Boosts Amgens Revenues in the Anti-Inflammation Segment
10:09AM  How Gilead Sciences Is Strengthening Its Presence in HIV Segment
09:50AM  Bi-monthly injection blocks HIV in study from J&J and GSK Reuters
08:34AM  Johnson & Johnson HIV combination succeeds in mid-stage study Reuters
08:20AM  5 Income Juggernauts You Can Safely Buy in Your 80s at Motley Fool
08:16AM  These 2 Companies Are Winning in the Clinic at Motley Fool
08:04AM  Milestone in HIV as Every-Other-Month Shot Blocks Virus at Bloomberg
Nov-02-15 05:17PM  Will Geron (GERN) Post a Wider-than-Expected Loss in Q3?
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand name; oral care products under the LISTERINE brand name; skin care products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, LUBRIDERM, NEUTROGENA, and RoC brand names; women's health products, such as sanitary pads under the STAYFREE and CAREFREE, and o.b. tampon brand names; wound care products, including adhesive bandages and first aid products under the BAND-AID and NEOSPORIN brand names; and nutritional products comprising no calorie sweetener under the SPLENDA brand name. This segment also offers over-the-counter medicines, including acetaminophen products under the TYLENOL brand name; cold, flu, and allergy products under the SUDAFED brand name; allergy products under the BENADRYL and ZYRTEC brand names; ibuprofen products under the MOTRIN IB brand name; and heartburn products under the PEPCID brand name. The Pharmaceutical segment provides various products in the areas of immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment offers orthopaedic, and trauma and neurological products; general surgery, and biosurgical and energy products; products to treat cardiovascular disease; infection prevention products; diagnostics products; blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company distributes its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ullmann Michael HVP, General CounselNov 20Option Exercise58.3422,6261,320,00194,878Nov 24 01:00 PM
Ullmann Michael HVP, General CounselNov 20Sale102.4717,6501,808,54377,228Nov 24 01:00 PM
Caruso Dominic JVP, Finance; CFONov 02Option Exercise58.3420,5691,199,995109,303Nov 04 05:05 PM
Caruso Dominic JVP, Finance; CFONov 02Sale102.2120,5692,102,42388,734Nov 04 05:05 PM
Kapusta Ronald AController, CAOOct 23Option Exercise58.346,239363,98327,042Oct 27 03:38 PM
Kapusta Ronald AController, CAOOct 23Sale99.686,239621,90420,803Oct 27 03:38 PM
PRINCE CHARLESDirectorAug 06Buy99.252,500248,13225,645Aug 10 12:49 PM
PRINCE CHARLESDirectorJun 02Buy99.222,500248,05023,145Jun 03 05:20 PM
Stoffels PaulusChief Scientific OfficerApr 28Option Exercise64.43228,68314,733,404281,723Apr 30 04:56 PM
Stoffels PaulusChief Scientific OfficerApr 28Sale100.73187,25018,862,14294,473Apr 30 04:56 PM
Fasolo PeterVP, Global Human ResourcesMar 05Option Exercise65.37115,3077,537,619147,895Mar 09 05:14 PM
Fasolo PeterVP, Global Human ResourcesMar 05Sale102.40115,30711,807,86332,588Mar 09 05:14 PM
Stoffels PaulusChief Scientific OfficerFeb 09Option Exercise0.0029,073064,647Feb 11 08:16 PM
Caruso Dominic JVP, Finance; CFOFeb 09Option Exercise0.0031,5370101,324Feb 11 08:16 PM
Fasolo PeterVP, Global Human ResourcesFeb 09Option Exercise0.0020,935042,109Feb 11 08:16 PM
Gorsky AlexChairman, CEOFeb 09Option Exercise0.0042,1120130,173Feb 11 08:17 PM
COSGROVE STEPHEN JCorporate ControllerJan 16Option Exercise0.0011,1080101,402Jan 21 05:48 PM
Ullmann Michael HVP, General CounselJan 16Option Exercise0.008,949075,628Jan 21 05:48 PM
Caruso Dominic JVP, Finance; CFOJan 16Option Exercise0.0012,615074,216Jan 21 05:48 PM
Gorsky AlexChairman, CEOJan 16Option Exercise0.0016,845094,425Jan 21 05:48 PM
Stoffels PaulusChief Scientific OfficerJan 16Option Exercise0.0011,629039,539Jan 21 05:48 PM
Fasolo PeterVP, Global Human ResourcesJan 16Option Exercise0.008,374024,336Jan 21 05:48 PM
PETERSON SANDRA EGroup Worldwide ChairmanDec 17Option Exercise0.0021,689031,210Dec 19 04:37 PM